ArticlePLoS pathogens2025
Receptor transporter protein 4 (RTP4)-mediated repression of hepatitis C virus replication in mouse cells.
Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Hepatitis C virus (HCV) exhibits a narrow species tropism, causing robust infections only in humans and experimentally inoculated chimpanzees. While many host factors and restriction factors are known, many more likely remain unknown, which has limited the development of mouse or other small animal models for HCV. One putative restriction factor, the black flying fox orthologue of receptor transporter protein 4 (RTP4), was previously shown to potently inhibit viral genome replication of several ER-replicating RNA viruses. Since the murine but not the human ortholog is a potent inhibitor of HCV, we aimed to analyze the potential role for RTP4 in restricting HCV replication in mice. We demonstrated that mouse RTP4 (mmRTP4) functions as a dominant inhibitor of HCV infection. Via interspecies domain-mapping, we identified the zinc-finger domain (ZFD) of murine RTP4 as essential for inhibiting HCV, consistent with prior work. Introducing mmRTP4 into HCV-infected Huh7 cells profoundly reduced HCV NS5A protein production and virion release, demonstrating that mmRTP4 can also disrupt already established HCV replication complexes. This inhibition of HCV was not driven by induction of interferon-stimulated genes based on bulk RNA-seq, suggesting that mmRTP4 might directly act on HCV replication. Indeed, by in situ proximity ligation, we found that mmRTP4 directly associates with the HCV NS5A protein significantly more than human RTP4 during infection. However, disrupting RTP4 expression in mice expressing humanized alleles of CD81 and occludin (OCLN) - the species specific cellular factors mediating HCV uptake - did not increase permissiveness irrespective of the immunocompetence of the mice. Collectively, our work provides detailed insights into the role of RTP4 in contributing to HCV's narrow host range and will inform downstream development of a more comprehensive small-animal model for this important pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.